<u>Combined metagenomic- and culture-based approaches to investigate bacterial strain-level</u> <u>associations with medication-controlled mild-moderate atopic dermatitis</u>

- 3
- 4 Nicole M Lane Starr^{a,b}, Numan Al-Rayyan^a, Jennifer M Smith^a, Shelby Sandstrom^b, Mary
- 5 Hannah Swaney^b, Rauf Salamzade^b, Olivia Steidl^a, Lindsay R Kalan^{b,c,d,*}, Anne Marie Singh^{a,b,e,*}
- 6
- ^a Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin,
- 8 Madison, WI, USA
- 9 ^b Department of Medical Microbiology and Immunology, School of Medicine and Public Health,
- 10 University of Wisconsin, Madison, WI, USA
- ^c Department of Medicine, Division of Infectious Disease, School of Medicine and Public
- 12 Health, University of Wisconsin, Madison, WI, USA
- 13 ^d M.G. DeGroote Institue for Infectious Disease Research, David Braley Centre for Antibiotic
- 14 Discovery, Department of Biochemistry and Biomedical Sciences, McMaster University,
- 15 Hamilton, Ontario, Canada
- ^e Department of Dermatology, School of Medicine and Public Health, University of Wisconsin,
- 17 Madison, WI, USA
- 18
- 19 *Contributed equally
- 20

21 Corresponding Authors

- 22 Anne Marie Singh, MD
- 23 600 Highland Avenue
- 24 Clinical Sciences Center K/9th Floor
- 25 Madison, WI 53792
- 26 Phone: 608-265-2605
- 27 Email: <u>amsingh@wisc.edu</u>
- 28
- 29 Lindsay Kalan, PhD
- 30 Email: <u>kalanlr@mcmaster.ca</u>

3132 <u>ABSTRACT</u>

- 33 Background: The skin microbiome is disrupted in atopic dermatitis (AD). Existing research
- 34 focuses on moderate-severe, unmedicated disease.
- 35 <u>Objective:</u> Investigate metagenomic- and culture-based bacterial strain-level differences in mild,
- 36 medicated AD, and the effects these have on human keratinocytes (HK).
- 37 <u>Methods</u>: Skin swabs from anterior forearms were collected from 20 pediatric participants; 11
- 38 participants with AD sampled at lesional and nonlesional sites and 9 age- and sex-matched
- 39 controls). Participants had primarily mild-moderate AD and maintained medication use. Samples
- 40 were processed for microbial metagenomic sequencing and bacterial isolation. Isolates identified
- 41 as *S. aureus* were tested for enterotoxin production. HK cultures were treated with cell free
- 42 conditioned media from representative *Staphylococcus* species to measure barrier effects.
- 43 Results: Metagenomic sequencing identified significant differences in microbiome composition
- 44 between AD and control groups. Differences were seen at the species- and strain-levels for
- 45 *Staphylococci*, with *S. aureus* only found in AD participants and differences in *S. epidermidis*
- 46 strains between control and AD swabs. These strains showed differences in toxin gene presence,

- 47 which was confirmed *in vitro* for *S. aureus* enterotoxins. The strain from the most severe AD
- 48 participant produced enterotoxin B levels >100-fold higher than the other strains (p<0.001).
- 49 Strains also displayed differential effects on HK metabolism and barrier function.
- 50 <u>Conclusions</u>: Strain level differences in toxin genes from *Staphylococcus* strains may explain
- 51 varying effects on HK, with S. aureus and non-aureus strains negatively impacting viability and
- 52 barrier function. These differences are likely important in AD pathogenesis.
- 53

54 KEY MESSAGES

- Staphylococcal strain effects, more so than species effects, impact keratinocyte barrier
 function and metabolism, suggesting that strain level differences, and not species-level,
 may be critical in AD pathogenesis.
 - The microbiome from mild, medicated atopic dermatitis patients harbor *Staphylococcus* strains with detrimental effects on skin barrier, and may not only be mediated by *S. aureus*.
- 60 61

65

58

59

62 <u>CAPSULE SUMMARY</u>

63 Patients with mild atopic dermatitis controlled by medication may still harbor strains of

64 *Staphylococcus spp.* that carry toxins that negatively impact skin barrier function.

66 <u>KEY WORDS</u>

- 67 Atopic dermatitis, skin microbiome, *Staphylococcus aureus, Staphylococcus epidermidis*,
- 68 metagenomics, bacterial isolation, human keratinocytes
- 69

84

70 ABBREVIATIONS

- 71 AD: atopic dermatitis
- 72 AMP: antimicrobial peptides
- 73 BHI: brain heart infusion
- 74 BHIT: brain heart infusion + 0.1% Tween 80
- 75 CFCM: cell free conditioned media
- 76 CoNS: coagulase negative Staphylococci
- 77 DM: differentiation media
- 78 HK: human keratinocyte(s)
- 79 MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- 80 p_{adj} : adjusted p value (using Bonferroni)
- 81 SEB: staphylococcal enterotoxin B
- 82 ST: strain type
- 83 TEER: trans-epithelial electrical resistance

85 ACKNOWLEDGMENTS

- 86 Our sincerest gratitude to the participants and their families who made this research possible. We
- 87 would also like to thank members of both the Kalan and Singh labs for their valuable feedback
- 88 during both the experimental and writing phases, especially J.Z. Alex Cheong and Elizabeth C.
- 89 Townsend.
- 9091 FUNDING
- 92 NIAID K23-AI100995 (AMS)

- 93 University of Wisconsin School of Medicine and Public Health (AMS)
- 94 5T32AI007635-20 (NMLS)
- 95 NIAID U19AI142720 (LRK)
- 96 NIGMS R35GM137828 (LRK)
- 97

98 DATA SUMMARY

- 99 Genomic data is available on the National Center for Biotechnology Information (NCBI)
- 100 database under BioProjects PRJNA830888.
- 101

102 CONFLICTS OF INTEREST

- 103 AMS serves on the Data Safety Monitoring Board for Siolta Therapeutics Inc and receives
- 104 consulting fees from Incyte and Genentech.
- 105 LRK conducts research with the 3M company.
- 106 The other authors have no conflicts to declare.
- 107
- 108
- 109
- 110

111 **INTRODUCTION**

112 Atopic dermatitis (AD) is the most common inflammatory skin disease in children, with recent

- 113 estimates suggesting as many as 1 in 5 children experience AD, with 80% exhibiting symptoms
- within the first 6 years of life¹⁻³. AD is characterized by recurrent eczematous lesional skin sites. 114
- During flares, these erythematous patches are associated with pruritis, exudation, blistering, and 115
- 116 lichenification, which can cause loss of sleep, poor mental health, and decreases in school/work
- performance^{1,5}. It has been proposed that disruptions to the skin barrier during AD flares 117
- promote AD pathogenesis^{6,7}. Numerous causes have been proposed for this disruption of the skin 118
- barrier, including genetic mutations (for example, in the filaggrin gene)⁸, immune dysregulation 119 (classically characterized by Th2 and IgE predominance)^{4,6,7}, environmental triggers (such as 120
- detergents and epicutaneous protease exposure)⁹⁻¹¹, and alterations in the skin microbiome 121
- (particularly overgrowth of *Staphylococcus aureus*)^{12,13}. 122
- 123
- 124
- The microbiota plays a critical role in the maturation and function of the skin barrier¹⁴, including pH balance^{15–17}, water retention¹⁸, keratinocyte differentiation^{19,20}, wound healing^{21–24}, innate^{25,26} and adaptive immune responses^{16,27,28}, and pathogen competition^{29–31}. Commensal skin bacteria, 125
- 126
- such as *Staphylococcus epidermidis*, produce antimicrobial peptides (AMPs) which are 127
- bactericidal and increase keratinocyte production of host AMPs^{29,32,33}. These bacterial AMPs are 128
- active against S. aureus and are depleted on AD skin²⁹. In contrast, S. aureus is important in AD 129
- pathogenesis. Multiple studies have shown an increased prevalence of S. aureus on the skin of 130
- AD patients, particularly on lesional sites^{34,35}. S. aureus is known to produce a number of toxins, 131
- 132 with staphylococcal enterotoxin B (SEB) in particular associated with more severe $AD^{36,37}$.
- 133 However, existing studies, including those associating increased *S. aureus* with lesional skin,
- 134 have largely focused on moderate to severe participants while holding AD medications, and have
- 135 focused on the microbiome at the genus and species levels. Whether S. aureus plays a similarly
- 136 important role in less severe or well-controlled disease remains less well understood.
- 137 Additionally, variability at the strain-level in AD progression is only beginning to be addressed,
- with early studies suggesting strains from severe AD subjects more negatively impact the skin in 138
- a murine model^{35,38}. 139
- 140

141 **METHODS**

142 **Overall approach**

- 143 Skin swabs were collected from 20 participants aged 0.5-14 years for metagenmic analysis of the
- 144 microbiome. When present, lesional samples were collected in addition to matched nonlesional
- 145 samples. In contrast to prior studies, AD participants were primarily mild-moderate and
- 146 continued use of topical therapies to control disease, mimicking real-world clinical scenarios.
- 147 Shotgun metagenomic and culture-based approaches were used to evaluate the microbial
- 148 communities associated with these samples. To determine the effects of strain variation on
- 149 keratinocyte viability and barrier integrity, keratinocyte cultures were exposed to conditioned
- 150 media containing secreted metabolites from select Staphylococcus isolates derived from
- participants with a range of clinical presentations. 151
- 152

153 Patient recruitment and classification

- 154 Recruitment occurred at the University of Wisconsin (UW)—Madison's Pediatric Allergy-
- 155 Immunology and Dermatology clinics. Consent for the study and publication of results was
- obtained from participants' legal representatives. Approval was granted by the UW School of 156

- 157 Medicine and Public Health's Institutional Review Board. Participants were assigned non-
- 158 identifying subject IDs for the study. Atopic dermatitis was defined as board certified pediatric
- 159 allergist or pediatric dermatologist diagnosis with typical signs and symptoms of disease
- 160 (eczematous dermatitis with typical morphology and distribution) using Hanifan and Reijka
- criteria. AD severity was determined as previously described using guidelines based criteria³⁹. 161
- 162 Age and sex matched controls were recruited if they had no current eczematous rash, no prior
- 163 history of atopic dermatitis, and were not using any topical medication. See Supplemental
- 164 Methods for criteria for other allergic disease classification.
- 165

166 **Sample collection**

- Skin swabs were collected from 20 pediatric participants using standard Copan swabs for 167
- 168 metagenomic analysis and eSwabs (Copan) to obtain live isolates. Lesional (if present) and
- 169 nonlesional swabs were collected from all participants. See Supplemental Methods for full
- 170 details.
- 171

172 Metagenomic library preparation and analysis

- DNA extraction was done as previously described⁴⁰. Samples were sent to University of 173
- 174 Minnesota Genomics Center for library preparation and metagenomic sequencing. Resulting
- 175 FASTQ files were processed using quality filtering, adapter removal, human decontamination,
- and tandem repeat removal as described previously⁴⁰. Taxonomic classification and abundance estimation was performed using Kraken2 (v2.0.8-beta)⁴¹ and Bracken (v2.5)⁴². Reads assigned as 176
- 177
- 178 Homo sapiens or that were unclassified at the genus level were filtered out. Decontam (v1.16.0)
- 179 was then used to identify and remove contaminant reads. See Supplemental Methods for
- additional details and Supplemental Figure 2 for read counts at each step. StrainGST (v1.3.3)⁴³ 180
- 181 was used to infer the presence and relative abundance of specific Staphylococcus strains, using a
- set of 230 representative genomes from across the genus⁴⁴. PubMLST was used to determine 182
- 183 strain types (ST) for *S. epidermidis*⁴⁵.

184

185 **Bacterial isolation and identification**

- Single isolates were obtained through selective culturing on multiple media types, until single 186
- colonies were obtained. Sanger sequencing on the full-length 16S rRNA gene was used for 187
- 188 taxonomic classification. See Supplemental Methods for full detail.
- 189

190 Whole genome sequencing

- 191 Bacteria identified as *Staphylococcus* were sent for whole genome sequencing at SeqCenter 192 (Pittsburgh, PA) using the Illumina DNA Prep kit and IDT 10 bp UDI indices, with sequencing
- 193 performed on an Illumina NextSeq 2000. Demultiplexing, quality control, and adapter trimming
- 194 was done with bcl-convert (v3.9.3). These genomes were then used to generate a phylogenetic
- tree with autoMLST in the *de novo* mode and concatenated alignment functions⁴⁶. The resulting 195 tree was visualized using iTOL⁴⁷. Gene-calling and standard-annotation was performed using 196
- PROKKA (v1.13)⁴⁸. Toxin genes were identified through DIAMOND BLASTp alignment to the 197
- full Virulence Finder Database⁴⁹ download in Jan 2023, retaining the best hit per query based on 198
- 199 bitscore with additional filters to retain only alignments exhibiting a maximum E-value of 1e-5, a
- 200 minimum percent identity of 50%, and minimum query and subject coverages of 70%.
- 201

202 Generation of staphylococcal cell free supernatants

203 Staphylococcus isolates were grown from stock on trypticase soy agar overnight at 37 °C. Single

- colonies were then grown in trypticase soy broth overnight at 37 °C with shaking. The following
- morning, liquid cultures were used to inoculate 50 mL supplemented keratinocyte growth media
- 206 (see Supplemental Methods for recipe) to a starting OD_{600} of 0.1, followed by incubation at 37
- ²⁰⁷ °C with shaking. OD_{600} was read every 2 hr until an OD_{600} of 0.7 was reached (range 0.693-
- 1.156, average 0.774; typically 3-7 hrs). The cultures were centrifuged at 3220 x g for 10 min.
 The supernatants were collected and passed through a Watman cellulose Grade 1 filter paper (GE)
- 209 The supernatants were conected and passed through a watman centroise Grade 1 filter paper (GE 210 Healthcare Life Sciences), then through a $0.2 \,\mu m$ pore filter. Supernatants were stored at -20 °C
- 210 Interface the sciences), then through a 0.2 µm pore finter. Superhatants were stored at -20° C 211 until use. Cultures were serially diluted for CFU plating immediately following inoculation and
- immediately preceding collection to confirm similar CFUs across strains (average of 2.64×10^9
- 213 CFU/mL).
- 214

215 In vitro enterotoxin assay

216 Staphylococcus isolates from stock were grown on BHI agar overnight at 37 °C. Single colonies

- 217 were grown in 3 mL BHI liquid culture overnight at 37 °C with shaking. The next day, the
- cultures were centrifuged at 3500 x g for 5 min. The supernatants were collected and passed
- through a pore filter ($0.2 \mu m$). Enterotoxin levels were then measured using the BioPharm
- 220 Ridascreen kit according to manufacturer's instructions.
- 221

222 MTT assay

Effects of staphylococcal cell free supernatants on neonatal human keratinocyte (HK; American Type Culture Collection (ATCC; Manassas, Virginia)) cell viability were assessed using the 3-

- 225 (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay (Roche
- 226 Diagnostics, Mannheim, Germany) per manufacturer instructions. See Supplemental Methods for
- full description.
- 228

229 TEER assay

- HKs were also used for the trans-epithelial electrical resistance (TEER) assay. The cells were
 cultured in HK media on a semipermeable filter insert in a 5% CO₂ atmosphere at 37 °C for 24
- hrs until they reached confluence. They were then switched to a differentiation medium (DM;
- 233 DMEM medium supplemented with 1.8 mM calcium ion and 4 mM glutamine (Thermo Fisher
- Scientific)) alone (Control) or DM containing one of the *Staphylococcus* supernatants diluted to
- $1*10^{\circ}$ CFU/mL. The integrity of the HK monolayer was verified by measuring the TEER assay
- after 2 days of treatment. Three independent replicates were used to calculate the results. The
- electrical resistance, measured in ohms, of an empty insert was subtracted from that of the insertwith cells to yield the resistance of the cells. The electrical resistance was then multiplied by the
- area of the insert to determine the TEER. Results are expressed as the percentage change in
- TEER, which reflects the change in resistance after 2 days of treatment normalized to the TEER
- 241 value of the control (DM alone).
- 242

243 Statistical analysis

- R (version 4.2.0) was used to do all analysis and figure generation. A Kruskal-Wallis test was
- 245 used to compare select taxonomic levels and Shannon Diversity Index. PERMANOVA testing
- 246 was used with Bray-Curtis dissimilarity estimates. These calculations were done on relative
- abundance set to 100% for microbes, bacteria, or *Staphylococcus*, where appropriate. A t-test
- 248 was used to compare enterotoxin levels. Following a significant ANOVA, pairwise t-tests were

- 249 used to compare the MTT and TEER effects of the *Staphylococcus* isolates to media controls,
- 250 with a Bonferroni correction used to account for multiple testing.

251 <u>RESULTS</u>

252 Clinical characteristics and sample collection

- 253 Twenty pediatric participants, aged 5 months to 14 years, were recruited from the University of
- 254 Wisconsin Pediatric Allergy-Immunology and Dermatology Clinics (Table 1). One control
- 255 participant was omitted due to having a parent-reported history of atopic dermatitis (AD) but no
- 256 physician diagnosis and no symptoms of disease. The remaining participants consisted of 8
- 257 healthy controls, and 11 with diagnosed AD, primarily mild-moderate in severity. Participants
- with AD were not asked to halt usage of topical treatments (Supplemental Table 1). Skin swabs
- 259 collected from participants were classified as control, lesional, or nonlesional and were processed
- 260 for DNA extraction and metagenomic analysis and untargeted bacterial isolation.
- 261

262 Skin metagenomes from well-controlled AD participants resemble controls

- 263 Metagenomic analysis of skin swabs was completed to provide a comprehensive view of the
- 264 microbiome across participants. After filtering and quality control, the majority of reads (>97%)
- were identified as Bacteria (Fig 1A). The remaining 3% of reads mapped to either Eukaryota or
- 266 Viral databases. The dominant bacterial genera were consistent with previous reports of pediatric
- skin—*Streptococcus*, *Cutibacterium*, *Micrococcus*, *Staphylococcus* (Figure 1B). Of note, the
- 268 Eukaryota were dominated by *Malassezia restricta*, but there were no significant differences
- across genera (Supplemental Fig 3A). Interestingly, viral relative abundance was elevated in AD
- 270 ($p_{adj}=0.010$). This was likely driven by the presence of *Escherichia virus T4*, which was only
- identified in AD participants (p=0.004) (Supplemental Fig 3B). Molluscum contagiosum virus,
 which is associated with skin infection, was also present on the skin of several participants, but
- which is associated with skin infection, was also present on the skin of several p was not significantly different among the groups (Supplemental Fig 3B).
- 274
- Alpha (within-sample) diversity of the bacteria, as measured by the Shannon Diversity Index, did not significantly differ between the 3 groups (Figure 2A), nor when considering combined AD
- 277 (pooled lesional and nonlesional samples) vs control samples. However, a trend emerged
- 278 showing lower diversity but greater evenness in the lesional group compared to control
- (Supplemental Fig 4). A similar trend was noted with the combined AD group for evenness
- 280 (p=0.07). Similarly, beta (between-sample) diversity, measured by Bray-Curtis dissimilarity,
- showed weak grouping of controls vs combined AD (p=0.056).
- 282

283 Staphylococcal strain variation by AD status

- Staphylococcus species are amongst the most dominant taxa on human skin, and blooms of *S. aureus* have been associated with AD flares. Focusing on the *Staphylococcus* species within the
 metagenomes showed large intra-individual variability (Fig 3A). Although the proportion of *Staphylococcus* species present in the three groups did not significantly differ, the total number
 of different *Staphylococcus* species present in AD participants trended higher (Fig 3B; p=0.15).
 Notably, we did find a decrease in Shannon Diversity when comparing combined AD vs control
 (p=0.048; Fig 3C).
- 291
- 292 To determine if specific strains of Staphylococci vary by AD status, we classified the
- 293 *Staphylococcus* strains in metagenomes using StrainGST⁴³. This analysis showed a striking lack
- of *S. epidermidis FDAARGOS_1361* (strain type (ST) 153) in lesional samples, but was present

in 5/7 control samples and 4/8 of nonlesional samples (Fig 3D). Conversely, 3 other strains of S.

epidermidis were present only in AD swabs (ST 5, 89, 387). These data suggest that the

association of *S. epidermidis* with disease activity may be strain dependent. Using StrainGST, we

- 298 observed *S. aureus* strains only in AD samples, specifically in the nonlesional swabs. Strains of
- 299 S. warneri and S. saprophyticus, skin commensals that may act opportunistically^{50,51}, were also
- 300 only observed in AD samples (Fig 3D).
- 301

302 Isolation and identification of live bacterial isolates

To determine the role different strains may be playing in AD pathogenesis, we performed
 untargeted bacterial isolation. Using four different media to capture greater microbial diversity,

- 305 601 isolates from 26 swabs were obtained. Full length 16S rRNA gene sequencing was used to
- taxonomically classify each isolate, resulting in the classification of 22 genera—13 among the
- 307 305 isolates from control swabs, 10 from the 84 lesional isolates, and 14 from the 210
- nonlesional isolates (Supplemental Table 2). Of those, 93% were genera represented in themetagenomes. Actinobacteria were the most abundantly represented phylum, followed by
- Firmicutes and then Proteobacteria in both the metagenomic- and culture-based approaches. Of
- 311 note, control swabs had >50% more isolates collected than from nonlesional swabs, which, in
- 312 turn, had twice the number of isolates as lesional swabs. *Micrococcus* was the most abundantly
- 313 cultured genera from control samples, while *Staphylococcus spp*. (specifically *aureus*, *capitis*,
- 314 *epidermidis, hominis, saprophyticus, succinus,* and *warneri*) were the most abundantly isolated
- in lesional and nonlesional swabs (Supplemental Table 2). Combined, these two genera
- accounted for >40% of all isolates. Strikingly, the proportion of isolates that are *Staphylococcus*
- 317 *spp.* rose greatly in the AD samples, particularly those from nonlesional sites.
- 318

319 Toxins are elevated in AD-associated Staphylococci

To better understand the role of Staphylococci strain-level differences on AD, we utilized the 320 321 above-described isolate library. Staphylococci strains representing species isolated across 322 participants were subject to whole genome sequencing. From this, a phylogenetic tree was 323 generated showing relatedness of the selected strains (Figure 4A). Of note, all S. aureus isolates 324 were collected from moderate and severe AD participants. Conversely, all S. epidermidis and S. 325 hominis isolates were from mild AD or control participants. The S. capitis strains were split into 326 2 clusters, one comprised of moderate-severe AD participants and the other associated with a 327 single mild participant. Genes encoding toxin production in each genome were predicted using 328 the Virulence Factor Database. We noted three patterns for genes encoding toxins—those 329 universally present (not shown), those present in a specific species, and those present in only 330 select isolates. All isolates, even coagulase negative Staphylococci (CoNS), contained at least 331 five toxin-associated genes. As expected, S. aureus strains contained increased enterotoxin, 332 hemolysin, and leukocidin genes (Fig 4B). Only 1/3 S. aureus strains isolated encoded for seb. 333 This S. aureus strain, designated LK1493, was isolated from a participant recorded as having 334 severe disease. To confirm the genomic predictions, the production of enterotoxins in each S. 335 aureus isolate was tested in vitro, confirming high levels of SEB production by LK1493 (p<0.001) (Fig 4C).

336 337

338 Effects of *Staphylococcus* supernatants on keratinocytes *in vitro*

- 339 To test the *in vitro* effects of these differences on keratinocytes, cell free conditioned media
- 340 (CFCM) derived from the *Staphylococcus* isolates were incubated with keratinocytes to

- 341 investigate cell viability and barrier integrity using MTT and TEER assays, respectively. Isolates
- 342 from AD swabs significantly decreased cell viability (Fig 5A) and barrier function (Fig 5B).
- 343 However, there was wide variability within each group.
- 344
- To investigate the variability within in each group, we first compared among species (Fig 5C,
- D). *S. hominis* species isolated from control swabs had no effect on cell viability, while *S.*
- 347 *hominis* species from AD lesional swabs were detrimental. Indeed, many *Staphylococcus* species
- isolated from lesional swabs significantly impaired TEER ($p_{adj} < 0.05$). We next examined each
- isolate (Fig 5E, F). We found intriguing differences driven by the strain of Staphylococcus
- tested. For example, *S. hominis* LK2134, isolated from a control participant, showed a trend towards improved barrier function ($p_{adi}=0.12$, p=0.005), whereas *S. hominis* LK2024, isolated
- from a lesional swab showed the most detrimental effect on barrier function (p_{adj} -0.12, p=0.003), whereas 5. *hommus* EK2024, isolated from a lesional swab showed the most detrimental effect on barrier function (p_{adj} <1E-10). S.
- 353 *warneri* LK1434 significantly decreased MTT (p_{adj}=0.006) but not TEER, whereas *S. warneri*
- LK1908 and LK2055 significantly decreased TEER ($p_{adj} < 1E-4$) but not MTT. None of the S.
- 355 *epidermidis* isolates significantly impacted MTT, although 2 decreased TEER (p_{adj}<0.001). All
- isolates of *S. capitis* significantly decreased TEER ($p_{adj} < 0.005$), but only 1 trended towards a
- decrease in MTT (p_{adj}=0.060). Similarly, 2 strains of *S. aureus* significantly decreased TEER
- 358 $(p_{adj} < 1E-4)$, while the third trended towards a decrease in MTT $(p_{adj} = 0.14)$.
- 359

360

361 **DISCUSSION**

The skin microbiome is critical in maintaining proper functioning of the skin barrier, and previous research has focused on the role of *S. aureus* in moderate-severe AD while medications are held. In this setting, the relative abundance of *S. aureus* has been shown to increase during

- acute disease flares 12,13 . In addition, *S. aureus* has also been shown to produce toxins,
- particularly SEB, which are associated with more severe disease 36,37 . However, there is limited
- 367 research into medication-controlled AD, which is more reflective of the clinical setting.
- 368

369 In our medicated cohort, we did not observe the emergence *S. aureus* blooms reported in

- previous studies enrolling unmedicated AD, even in lesional samples. When *S. aureus* was
- detected, it was primarily identified from nonlesional AD swabs. This is similar to a previous
- study that found mitigation of *S. aureus* overgrowth when taking medication¹³. As topical
- 373 corticosteroids have been shown to decrease *S. aureus* bioburden⁵², our data together with the
- 374 previous work, suggests that the interventions to manage AD are decreasing *S. aureus*
- overgrowth, despite disease flares.
- 376

377 Differences in *Staphylococcus* strains were present, including in CoNS. A strain of *S*.

epidermidis (ST153) was primarily associated with healthy participants. This strain was also 378 379 associated with healthy volunteers in a study of catheter-related bacteremia⁵³. Conversely, 380 metagenomes from AD lesions contained number of other S. epidermidis strains. Although previous studies in AD have suggested potential protective effects of S. epidermidis, it can 381 382 behave as an opportunistic pathogen. The pathogenicity of S. epidermidis seems to vary greatly by strain, with certain strains being associated with health and others with disease^{35,54,55}. Thus, 383 384 these data suggest the importance of strain-level differences in both S. aureus and non-aureus 385 Staphylococcus species in AD disease expression and severity.

386

In addition, we observed marked differences in toxin gene presence across the Staphylococcal
isolates. All 3 *S. aureus* strains, isolated from moderate and severe participants, encoded for
more toxin genes than other strains. One *S. aureus* strain (isolated from a severe patient),
contained the *seb* gene and expressed this protein at high levels *in vitro*. Previous studies have
suggested SEB is associated with more severe AD^{36,37}, likely due to its cytotoxic effects which
disrupt barrier function⁵⁶.

393

394 Importantly, our data evaluating keratinocyte metabolism and barrier function after exposure to 395 secreted factors from diverse Staphylococci species demonstrates that many Staphylococcal 396 strains are capable of disrupting keratinocyte function, even in the absence of enterotoxin 397 production. Additionally, keratinocyte dysfunction occurred across several species, and was 398 strain dependent. In general, S. aureus and S. capitis were associated with deleterious effects on 399 barrier function, while S. epidermidis and S. warneri had strain-level varied impacts as measured by TEER. Finally, different strains of S. hominis induced opposing effects on keratinocyte 400 401 integrity as measured by MTT. Ongoing research will attempt to clarify the drivers of these 402 differential effects.

403

404 Taken together, our data underscore the importance of bacterial strain in AD disease expression

- 405 and pathogenesis, and suggest that topical steroids can be effective in controlling *S. aureus*
- 406 overgrowth. It is worth noting that this was a small cross-sectional study, with participants

- 407 covering a range of developmental stages. The skin microbiome can change significantly from
- 408 infancy through puberty 60 , and controls were age and sex matched to help address this issue.
- Additionally, medications used varied somewhat among participants, which may have
- 410 differential impacts on the skin microbiome. Thus, future research will add additional
- 411 participants to clarify these effects, and to collect additional strains of *Staphylococcus*, as well as
- 412 expanding to genera beyond *Staphylococcus*.
- 413
- 414 The data presented demonstrate the critical role of strain-level differences in AD pathogenicity.
- 415 Strains differed with regard to presence and amount of toxins expressed, effect on keratinocyte
- 416 viability and barrier function. Additionally, deleterious effects were not exclusive to *S. aureus*.
- Thus, both inter- and intra-species differences impact AD pathogenesis, suggesting that strain-
- 418 level differences are important considerations in AD pathogenesis and disease expression.
- 419
- 420
- 421
- 422

423 <u>REFERENCES</u>

- Williams H, Robertson C, Stewart A, Aït-Khaled N, Anabwani G, Anderson R, et al. Worldwide
 variations in the prevalence of symptoms of atopic eczema in the international study of asthma and
 allergies in childhood. Journal of Allergy and Clinical Immunology [Internet]. 1999 [cited 2023
 Jan 27];103:125–38. Available from:
- 428 http://www.jacionline.org/article/S0091674999705361/fulltext
- 429 2. Mohn CH, Blix HS, Halvorsen JA, Nafstad P, Valberg M, Lagerløv P. Incidence Trends of Atopic
 430 Dermatitis in Infancy and Early Childhood in a Nationwide Prescription Registry Study in
 431 Norway. JAMA Netw Open [Internet]. 2018 [cited 2023 Jan 27];1. Available from:
 432 /pmc/articles/PMC6324394/
- A33 3. Perkin MR, Strachan DP, Williams HC, Kennedy CTC, Golding J. Natural history of atopic
 434 dermatitis and its relationship to serum total immunoglobulin E in a population-based birth cohort
 435 study. Pediatric Allergy and Immunology [Internet]. 2004 [cited 2023 Jan 28];15:221–9. Available
 436 from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1399-3038.2004.00160.x
- 437 4. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nature Reviews
 438 Disease Primers 2018 4:1 [Internet]. 2018 [cited 2023 Jan 27];4:1–20. Available from:
 439 https://www.nature.com/articles/s41572-018-0001-z
- 440 5. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, AÃ⁻t-Khaled N, et al. Global
 441 variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of
 442 Allergy and Clinical Immunology [Internet]. 2009 [cited 2023 Jan 27];124:1251-1258.e23.
 443 Available from: http://www.jacionline.org/article/S0091674909015358/fulltext
- 6. Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, Geha RS. Epicutaneous sensitization
 with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine
 after single exposure to aerosolized antigen in mice. J Clin Invest [Internet]. 1998 [cited 2023 Jan
 27];101:1614–22. Available from: http://www.jci.org
- Tran MM, Lefebvre DL, Dharma C, Dai D, Lou WYW, Subbarao P, et al. Predicting the atopic
 march: Results from the Canadian Healthy Infant Longitudinal Development Study. Journal of
 Allergy and Clinical Immunology [Internet]. 2018 [cited 2023 Jan 27];141:601-607.e8. Available
 from: http://www.jacionline.org/article/S009167491731480X/fulltext
- 452 8. Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Annals of
 453 Allergy, Asthma & Immunology [Internet]. 2020 [cited 2023 Jan 28];124:36–43. Available from:
 454 http://www.annallergy.org/article/S108112061931289X/fulltext
- 455 9. Moreno AS, Mcphee R, Arruda LK, Howell MD. Targeting the T Helper 2 Inflammatory Axis in
 456 Atopic Dermatitis. Int Arch Allergy Immunol [Internet]. 2016 [cited 2023 Jan 28];171:71–80.
 457 Available from: https://pubmed.ncbi.nlm.nih.gov/27846627/
- 10. Xian M, Wawrzyniak P, Rückert B, Duan S, Meng Y, Sokolowska M, et al. Anionic surfactants
 and commercial detergents decrease tight junction barrier integrity in human keratinocytes. J
 Allergy Clin Immunol [Internet]. 2016 [cited 2023 Feb 12];138:890-893.e9. Available from:
 https://pubmed.ncbi.nlm.nih.gov/27596709/
- 462 11. Celebi Sözener Z, Cevhertas L, Nadeau K, Akdis M, Akdis CA. Environmental factors in
 463 epithelial barrier dysfunction. J Allergy Clin Immunol [Internet]. 2020 [cited 2023 Feb
 464 12];145:1517–28. Available from: https://pubmed.ncbi.nlm.nih.gov/32507229/
- 465 12. Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and Atopic Dermatitis: A Complex
- 466 and Evolving Relationship. Vol. 26, Trends in Microbiology. Elsevier Ltd; 2018. p. 484–97.

467 Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin 13. 468 microbiome associated with disease flares and treatment in children with atopic dermatitis. 469 Genome Res [Internet]. 2012 [cited 2020 Jul 6];22:850–9. Available from: 470 /pmc/articles/PMC3337431/?report=abstract 471 Harris-Tryon TA, Grice EA. Microbiota and maintenance of skin barrier function. Science (1979) 14. 472 [Internet]. 2022 [cited 2023 Jan 27];376:940–5. Available from: 473 https://www.science.org/doi/10.1126/science.abo0693 474 15. Bomar L, Brugger SD, Yost BH, Davies SS, Lemon KP. Corynebacterium accolens Releases 475 Antipneumococcal Free Fatty Acids from Human Nostril and Skin Surface Triacylglycerols. mBio 476 [Internet]. 2016 [cited 2023 Jan 28];7. Available from: /pmc/articles/PMC4725001/ 477 Ridaura VK, Bouladoux N, Claesen J, Erin Chen Y, Byrd AL, Constantinides MG, et al. 16. 478 Contextual control of skin immunity and inflammation by Corynebacterium. Journal of 479 Experimental Medicine [Internet]. 2018 [cited 2020 Jul 1];215:785–99. Available from: 480 /pmc/articles/PMC5839758/?report=abstract 481 17. Nakatsuji T, Kao MC, Zhang L, Zouboulis CC, Gallo RL, Huang CM. Sebum free fatty acids 482 enhance the innate immune defense of human sebocytes by upregulating β -defensin-2 expression. 483 Journal of Investigative Dermatology [Internet]. 2010 [cited 2020 Jul 16]:130:985–94. Available 484 from: /pmc/articles/PMC3057125/?report=abstract 485 18. Nodake Y, Matsumoto S, Miura R, Honda H, Ishibashi G, Matsumoto S, et al. Pilot study on novel 486 skin care method by augmentation with Staphylococcus epidermidis, an autologous skin microbe -487 A blinded randomized clinical trial. J Dermatol Sci [Internet]. 2015 [cited 2023 Jan 27];79:119-488 26. Available from: http://www.jdsjournal.com/article/S0923181115001668/fulltext 489 19. Uberoi A, Bartow-McKenney C, Zheng O, Flowers L, Campbell A, Knight SAB, et al. 490 Commensal Microbiota Regulates Skin Barrier Function And Repair Via Signaling Through The 491 Aryl Hydrocarbon Receptor. Cell Host Microbe [Internet]. 2021 [cited 2023 Jan 28];29:1235. 492 Available from: /pmc/articles/PMC8364505/ 493 20. Zheng Y, Hunt RL, Villaruz AE, Fisher EL, Liu R, Liu Q, et al. Commensal Staphylococcus 494 epidermidis contributes to skin barrier homeostasis by generating protective ceramides. Cell Host 495 Microbe [Internet]. 2022 [cited 2023 Jan 28];30:301-313.e9. Available from: http://www.cell.com/article/S1931312822000403/fulltext 496 497 Kalan LR, Meisel JS, Loesche MA, Horwinski J, Soaita I, Chen X, et al. Strain- and Species-Level 21. 498 Variation in the Microbiome of Diabetic Wounds Is Associated with Clinical Outcomes and 499 Therapeutic Efficacy. Cell Host Microbe [Internet]. 2019 [cited 2020 Jul 2];25:641-655.e5. 500 Available from: /pmc/articles/PMC6526540/?report=abstract 501 di Domizio J, Belkhodja C, Chenuet P, Fries A, Murray T, Mondéjar PM, et al. The commensal 22. 502 skin microbiota triggers type I IFN-dependent innate repair responses in injured skin. Nature 503 Immunology 2020 21:9 [Internet]. 2020 [cited 2023 Jan 28];21:1034–45. Available from: 504 https://www.nature.com/articles/s41590-020-0721-6 505 Ubags ND, Trompette A, Pernot J, Nibbering B, Wong NC, Pattaroni C, et al. Microbiome-23. 506 induced antigen-presenting cell recruitment coordinates skin and lung allergic inflammation. 507 Journal of Allergy and Clinical Immunology [Internet]. 2021 [cited 2023 Jan 28];147:1049-508 1062.e7. Available from: http://www.jacionline.org/article/S0091674920309611/fulltext

Wang G, Sweren E, Liu H, Wier E, Alphonse MP, Chen R, et al. Bacteria Induce Skin

Regeneration via IL-1ß Signaling. Cell Host Microbe [Internet]. 2021 [cited 2023 Jan 28];29:777.

509

510

24.

511 Available from: /pmc/articles/PMC8122070/ 512 Sanford JA, Zhang LJ, Williams MR, Gangoiti JA, Huang CM, Gallo RL. Inhibition of HDAC8 25. 513 and HDAC9 by microbial short-chain fatty acids breaks immune tolerance of the epidermis to 514 TLR ligands. Sci Immunol [Internet]. 2016 [cited 2020 Jul 6];1. Available from: 515 https://immunology.sciencemag.org/content/1/4/eaah4609 516 26. Sanford JA, O'Neill AM, Zouboulis CC, Gallo RL. Short-chain fatty acids from Cutibacterium 517 acnes activate both a canonical and epigenetic inflammatory response in human sebocytes. J 518 Immunol [Internet]. 2019 [cited 2023 Jan 28];202:1767. Available from: 519 /pmc/articles/PMC7251550/ 520 27. Constantinides MG, Link VM, Tamoutounour S, Wong AC, Perez-Chaparro PJ, Han SJ, et al. 521 MAIT cells are imprinted by the microbiota in early life and promote tissue repair. Science 522 [Internet]. 2019 [cited 2023 Jan 28];366. Available from: /pmc/articles/PMC7603427/ 523 Legoux F, Bellet D, Daviaud C, el Morr Y, Darbois A, Niort K, et al. Microbial metabolites 28. 524 control the thymic development of mucosal-associated invariant T cells. Science (1979) [Internet]. 525 2019 [cited 2023 Jan 28];366:494–9. Available from: 526 https://www.science.org/doi/10.1126/science.aaw2719 527 29. Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, et al. Antimicrobials from human 528 skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic 529 dermatitis. Sci Transl Med [Internet]. 2017 [cited 2020 Jul 1];9:4680. Available from: 530 /pmc/articles/PMC5600545/?report=abstract 531 30. Bitschar K, Sauer B, Focken J, Dehmer H, Moos S, Konnerth M, et al. Lugdunin amplifies innate 532 immune responses in the skin in synergy with host- and microbiota-derived factors. Nat Commun 533 [Internet]. 2019 [cited 2020 Jul 13];10. Available from: https://doi.org/10.1038/s41467-019-534 10646-7 535 31. Claesen J, Spagnolo JB, Ramos SF, Kurita KL, Byrd AL, Aksenov AA, et al. A Cutibacterium 536 acnes antibiotic modulates human skin microbiota composition in hair follicles. Sci Transl Med 537 [Internet]. 2020 [cited 2023 Jan 28];12. Available from: /pmc/articles/PMC8478231/ 538 32. Braff MH, Bardan A, Nizet V, Gallo RL. Cutaneous defense mechanisms by antimicrobial 539 peptides. Journal of Investigative Dermatology [Internet]. 2005 [cited 2020 Jul 20];125:9–13. 540 Available from: http://www.jidonline.org/article/S0022202X1532340X/fulltext Lai Y, Cogen AL, Radek KA, Park HJ, MacLeod DT, Leichtle A, et al. Activation of TLR2 by a 541 33. 542 small molecule produced by staphylococcus epidermidis increases antimicrobial defense against 543 bacterial skin infections. Journal of Investigative Dermatology [Internet]. 2010 [cited 2020 Jul 544 9];130:2211–21. Available from: https://pubmed.ncbi.nlm.nih.gov/20463690/ 545 34. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. 546 British Journal of Dermatology [Internet]. 1974 [cited 2020 Jul 9];90:525–525. Available from: 547 http://doi.wiley.com/10.1111/j.1365-2133.1974.tb06447.x 548 Byrd AL, Deming C, Cassidy SKB, Harrison OJ, Ng WI, Conlan S, et al. Staphylococcus aureus 35. 549 and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis. Sci Transl 550 Med [Internet]. 2017 [cited 2020 Jul 8];9. Available from: 551 /pmc/articles/PMC5706545/?report=abstract

552	36.	Strange P, Skov L, Lisby S, Nielsen PL, Baadsgaard O. Staphylococcal Enterotoxin B Applied on
553		Intact Normal and Intact Atopic Skin Induces Dermatitis. Arch Dermatol [Internet]. 1996 [cited
554		2023 Jan 28];132:27–33. Available from:
555		https://jamanetwork.com/journals/jamadermatology/fullarticle/557399
556	37.	Breuer K, Kapp A, Werfel T. Bacterial infections and atopic dermatitis. Allergy [Internet]. 2001
557		[cited 2023 Jan 28];56:1034–41. Available from:
558		https://onlinelibrary.wiley.com/doi/full/10.1034/j.1398-9995.2001.00146.x
559	38.	Iwamoto K, Moriwaki M, Miyake R, Hide M. Staphylococcus aureus in atopic dermatitis: Strain-
560		specific cell wall proteins and skin immunity. Vol. 68, Allergology International. Japanese Society
561		of Allergology; 2019. p. 309–15.
562	39.	Li JC, Arkin LM, Makhija MM, Singh AM, Prevalence of food allergy diagnosis in pediatric
563		patients with atopic dermatitis referred to allergy and/or dermatology subspecialty clinics. Journal
564		of Allergy and Clinical Immunology: In Practice [Internet] 2022 [cited 2023 Jan 27]:10:2469–71
565		Available from: http://www.jaci-inpractice.org/article/S2213219822005773/fulltext
566	40	Swaney MH Sandstrom S Kalan LR Cobamide Sharing Is Predicted in the Human Skin
567	10.	Microbiome mSystems [Internet] 2022 [cited 2023 Jan 28]:7 Available from:
568		/nmc/articles/PMC9600381/
569	41	Wood DF Lu L Langmead B Improved metagenomic analysis with Kraken 2 Genome Biol
570	71.	[Internet] 2019 [cited 2023 Ian 28]:20 Available from: /pmc/articles/PMC6883579/
571	42	Lu I Breitwieser FP Thielen P Salzberg SI Bracken: Estimating species abundance in
572	72.	metagenomics data Peerl Comput Sci [Internet] 2017 [cited 2023 Jan 28]:2017:e104 Available
573		from: https://peeri com/articles/cs_10/
574	13	van Dijk I.P. Walker BI Straub TI Worby CI Grote A Schreiber HI et al StrainGE: a toolkit to
575	45.	track and characterize low shundance strains in complex microhial communities. Conome Riel
576		[Internet] 2022 [aited 2022 Jan 28]:22 Available from: /nme/orticles/DMC8000228/
570	4.4	Selemzede D. Chaong IZA. Sendetrom S. Swanay MH. Stubbandiaek DM. Sterr NL at al
577	44.	Salamzade R, Cheolig JZA, Sandstrom S, Swaney MH, Studbendieck RM, Starr NL, et al.
570		Evolutionally investigations of the biosynthetic diversity in the skin incrobionic using isaboc.
579		bioRXIV [Internet]. 2022 [Cited 2025 Feb 15];2022.04.20.488955. Available from:
500	45	https://www.diorxiv.org/content/10.1101/2022.04.20.488953v3
581	45.	Jolley KA, Bray JE, Malden MCJ. Open-access bacterial population genomics: BIGSdb software,
202 502		Eth 121/2 Association for the second matrix and the second matrix and the second secon
583	10	Feb 12];3. Available from: https://pubmed.ncbi.nim.nin.gov/30345391/
584	46.	Alanjary M, Steinke K, Ziemert N. AutoMLS I: an automated web server for generating multi-
585		locus species trees highlighting natural product potential. Nucleic Acids Res [Internet]. 2019 [cited
586	17	2023 Jan 28];4/:W2/6. Available from: /pmc/articles/PMC6602446/
587	47.	Letunic I, Bork P. Interactive Tree Of Life (1TOL) v5: an online tool for phylogenetic tree display
588		and annotation. Nucleic Acids Res [Internet]. 2021 [cited 2023 Jan 28];49:W293–6. Available
589		from: https://academic.oup.com/nar/article/49/W1/W293/6246398
590	48.	Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics [Internet]. 2014 [cited
591		2023 Jan 28];30:2068–9. Available from:
592		https://academic.oup.com/bioinformatics/article/30/14/2068/2390517
593	49.	Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, et al. VFDB: a reference database for bacterial
594		virulence factors. Nucleic Acids Res [Internet]. 2005 [cited 2023 Jan 28];33:D325. Available
595		from: /pmc/articles/PMC539962/

- 50. Kanuparthy A, Challa T, Meegada S, Siddamreddy S, Muppidi V. Staphylococcus warneri: Skin
 597 Commensal and a Rare Cause of Urinary Tract Infection. Cureus. 2020;
- 51. Silva KCS, Silva LOS, Silva GAA, Borges CL, Novaes E, Paccez JD, et al. Staphylococcus
 saprophyticus proteomic analyses elucidate differences in the protein repertories among clinical
 strains related to virulence and persistence. Pathogens. 2020;9.
- 52. Nørreslet LB, Edslev SM, Bregnhøj A, Sommerlund M, Ebbehøj NE, Andersen PS, et al. Topical
 corticosteroids reduce the density of Staphylococcus aureus in hand eczema. Journal of the
 European Academy of Dermatology & Venereology. 2022;36:e318–9.
- 604 53. Cherifi S, Byl B, Deplano A, Nonhoff C, Denis O, Hallin M. Comparative Epidemiology of
 605 Staphylococcus epidermidis Isolates from Patients with Catheter-Related Bacteremia and from
 606 Healthy Volunteers. J Clin Microbiol [Internet]. 2013 [cited 2023 Feb 12];51:1541. Available
 607 from: /pmc/articles/PMC3647944/
- 608 54. Méric G, Mageiros L, Pensar J, Laabei M, Yahara K, Pascoe B, et al. Disease-associated
 609 genotypes of the commensal skin bacterium Staphylococcus epidermidis. Nat Commun [Internet].
 610 2018 [cited 2020 Jul 27];9:1–11. Available from: www.nature.com/naturecommunications
- 611 55. Conlan S, Mijares LA, Becker J, Blakesley RW, Bouffard GG, Brooks S, et al. Staphylococcus
 612 epidermidis pan-genome sequence analysis reveals diversity of skin commensal and hospital
 613 infection-associated isolates. Genome Biol [Internet]. 2012 [cited 2020 Jul 8];13:R64. Available
 614 from: /pmc/articles/PMC4053731/?report=abstract
- 615 56. Campbell WN, Fitzpatrick M, Ding X, Jett M, Gemski P, Goldblum2 SE, et al. SEB is cytotoxic
 616 and alters EC barrier function through protein tyrosine phosphorylation in vitro. 1997.
- 57. Severn MM, Williams MR, Shahbandi A, Bunch ZL, Lyon LM, Nguyen A, et al. The Ubiquitous
 Human Skin Commensal Staphylococcus hominis Protects against Opportunistic Pathogens.
 mBio. 2022;13.
- 58. Vasconcellos D, Weng B, Wu P, Thompson G, Sutjita M. Staphylococcus hominis Infective
 Endocarditis Presenting with Embolic Splenic and Renal Infarcts and Spinal Discitis. Case Rep
 Infect Dis. 2022;2022:1–5.
- 59. Kuipers A, Stapels DAC, Weerwind LT, Ko YP, Ruyken M, Lee JC, et al. The Staphylococcus
 aureus polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect
 against phagocytosis. Microbiology (United Kingdom). 2016;162:1185–94.
- 626 60. Townsend EC, Kalan LR. The dynamic balance of the skin microbiome across the lifespan. 2023
 627 [cited 2023 Jan 27]; Available from: http://portlandpress.com/biochemsoctrans/article628 pdf/doi/10.1042/BST20220216/941724/bst-2022-0216c.pdf
- 61. Prince BT, Devonshire AL, Erickson KA, Bergerson J, Fuleihan D, Szychlinski C, et al.
 630 Regulatory T-cell populations in children are affected by age and food allergy diagnosis. J Allergy
 624 Clin January of Untermet 2017 Joint 2022 Each 121:140:1104.1106 al. Augiliable frame.
- 631 Clin Immunol [Internet]. 2017 [cited 2023 Feb 12];140:1194-1196.e16. Available from:
 632 https://pubmed.ncbi.nlm.nih.gov/28549988/
 633 Good and a state of the state of th
- 633 62. COVE JH, HOLLAND KT, COUNLIFFE WJ. The Vitamin Requirements of Staphylococci
 634 Isolated from Human Skin. Journal of Applied Bacteriology [Internet]. 1980 [cited 2023 Feb
 635 13];49:29–37. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365636 2672.1980.tb01041.x
- 63. Machado H, Weng LL, Dillon N, Seif Y, Holland M, Pekar JE, et al. Strain-Specific Metabolic
 638 Requirements Revealed by a Defined Minimal Medium for Systems Analyses of Staphylococcus

- aureus. Appl Environ Microbiol [Internet]. 2019 [cited 2023 Feb 13];85. Available from:
- 640 https://pubmed.ncbi.nlm.nih.gov/31471305/
- 641 64. Saheb Kashaf S, Proctor DM, Deming C, Saary P, Hölzer M, Mullikin J, et al. Integrating
 642 cultivation and metagenomics for a multi-kingdom view of skin microbiome diversity and
 643 functions. Nat Microbiol [Internet]. 2022 [cited 2023 Jan 28];7:169. Available from:
- 644 /pmc/articles/PMC8732310/
- 645
- 646

647 <u>TABLE 1</u>

648 Demographic data for the participants.

649

PARTICIPANTS	N (% of total)		
Total	19 (100%)		
Female	8 (42.11%)		
AGE	Years		
Range	0.46 - 14.02		
Median (IQR)	3.07 (1.74 - 6.82)		
RACE			
Asian	2 (10.53%)		
Black or African American	2 (10.53%)		
Other	1 (5.26%)		
White	14 (73.68%)		
AD SEVERITY			
None	8 (42.11%)		
Mild	7 (36.84%)		
Moderate	2 (10.53%)		
Severe	2 (10.53%)		

650

651

652

653 FIGURE LEGENDS

654

655 **FIGURE 1—Metagenomic analysis of skin swabs from AD and control groups**

Bar graphs of the relative abundances of kingdom-level data (A), with an inset to show
differences in Eukaryota and Viruses. Relative abundance plot of bacterial genera (B), with hue
corresponding to phylum, genera are ordered by phylum abundance. For both, each swab was
normalized to 100% relative abundance of all included taxa along the y-axis and bars are
grouped by AD status then ordered by age along the x-axis.

661

662 <u>FIGURE 2—Diversity metrics did not differ significantly by AD status</u>

- The Shannon Diversity Index (A) and Bray Curtis Dissimilarity (B) were calculated for allmetagenomes and then grouped by AD Status.
- 665

666 <u>FIGURE 3—Staphylococcus species and strain level variation by AD status</u>

- (A) Bar chart showing relative abundances of *Staphylococcus* species detected in each
 metagenome, grouped by AD status, ordered by age across the x-axis. (B) Bar chart showing the
- relative abundances of the top 5 *Staphylococcus* species (as called by Kraken/Braken), grouped
- by AD status. (C) Shannon diversity index of all *Staphylococcus* species (as called by
- 671 Kraken/Braken), grouped by AD Status. (D) *Staphylococcus* strains (as called by StrainGST),
- 672 grouped by AD status, ordered by age.
- 673

674 FIGURE 4—Toxins are elevated in AD-associated Staphylococci

- 675 (A) Phylogenetic tree of select cultured Staphylococcus strains. Sequenced whole genomes were 676 uploaded to autoMLST using de novo mode and concatenated alignment function. The resulting 677 tree was annotated with iTOL. Type strains are colored by species. Cultured strains are in black, 678 with # symbol indicating subject's AD severity (none: control, #: mild AD, ##: moderate AD, 679 ###: severe AD). (B) Heat map indicating presence of toxin genes observed in the whole genome sequences of those same selected Staphylococcus strains, as called by PROKKA. (C) In vitro 680 681 enterotoxin levels in the 3 putatively unique S. aureus strains show strain-level differences, with SE levels increasing with severity. Bar graph depict mean and se; subject label color denotes AD 682 683 severity; line represents positivity threshold.
- 684

685 FIGURE 5—Staphylococcus cell-free media differentially impacts keratinocyte function

Box plots showing effects of *Staphylococcus* cell-free conditioned-media on MTT (A, C, E) and TEER (B, D, F) assays, faceted by groups and colored by species. A & B show the MTT and TEER data, respectively, at the group-level (ie all isolates in the control group are pooled, as are all in the lesional and non-lesional groups). C & D show the MTT and TEER at species-level resolution. E & F illustrate MTT and TEER with each individual strain. Bonferroni adjusted pvalue symbols: + 0.15, .0.1, * 0.05, ** 0.01, ***0.001, **** 0.0001

692

693 Supplemental Methods

694 **Patient recruitment and classification**

Food allergy was diagnosed by a board certified pediatric-allergist immunologist with typical

696 signs and symptoms of immediate Ig-E mediated reaction (ex: hives, angioedema, vomiting, *etc.*)

697 together with evidence of allergic sensitization or oral food challenge as previously described⁶¹.

698 Other allergic disease diagnosis was determined by parental report of physician diagnosis and

- 699 confirmed by medical record review.
- 700

701 Sample collection

Swabs were obtained from the forearm by rolling the swab with moderate pressure 10 times over the designated area, and then by turning the swab 90 degrees and rolling the swab 10 additional times. Lesional swabs were collected from sites of active lesions and nonlesionsal swabs were obtained from healthy-appearing skin from a similar body site (for example, just adjacent to the lesion, or on the contralateral body site) in a similar fashion, or from the anterior forearm when no lesion was present. Swabs were then submerged in lysis buffer and stored at -80 °C for further analysis.

709

710 Bacterial isolation

711 Samples were thawed and 100 μ L were pipetted onto 4 media plates—brain heart infusion (BHI)

agar, BHI + 0.1% Tween 80 (BHIT) agar, blood agar, and mannitol salt agar. Glass beads were

713 used to spread the sample evenly across plates. After the beads were removed and the plates

dried, they were incubated at 28 $^{\circ}$ C for 2-3 days. At this time, morphologically unique colonies

715 were picked from the plates and streaked for isolation onto fresh plates of the same media type.

All plates were then returned to the 28 °C incubator. Every 2-3 days for 1 week, the original culture plates were checked for new colonies. An individual colony was picked from the pure

culture plates were checked for new colonies. An individual colony was picked from the pure cultures on the isolation plates and grown in BHIT liquid culture overnight at 37 °C. After the

719 cultures on the isolation plates and grown in Britt inquid culture overlight at 57 C 719 cultures were turbid, a 15% glycerol stock was prepared for storage at -80 °C.

720

Bacterial isolates from stock were grown on BHIT agar overnight at 37 °C. From these plates,
 one colony was inoculated into 3 mL liquid BHI + (0.1%) Tween and incubated with shaking at

723 37 °C overnight. The 16S rRNA gene was amplified using PCR. Briefly, 0.5 μL of the overnight

- culture was added to 24.5 μL of master mix (12.5 μL Econotaq PLUS green, 1 μL F primer 16S
- 725 8F (10 μ M), 1 μ L R Primer 16S 1492R (10 μ M), 10 μ L nuclease free water) and run on a
- thermocycler (95 °C for 10 min, [95 °C for 30 s, 54 °C for 30 s, 72 °C for 60 s] for 30 cycles, 72
 °C for 5 min, hold at 4 °C). Product was confirmed by running on a 1% agarose gel and then sent
 for Sanger sequencing at Functional Biosciences, Inc (Madison, WI).
- 729

730 Generation of staphylococcal cell free supernatants

731 Supplemented keratinocyte growth media was composed of 500 mL Medium 154 (Life

732 Technologies), 500 mL Keratinocyte Serum Free Media with calcium (Life Technologies), 5 mL

Human Keratinocyte Growth Serum (Life Technologies), 25 mg bovine pituitary extract (Life

Technologies), 0.0025 mg human recombinant epidermal growth factor (Life Technologies), 50

mg/mL L-proline (DOT Scientific Inc), 15 mg/mL nicotinic acid (DOT Scientific Inc), and 2

736 mg/mL pantothenic acid $(VWR)^{21,62,63}$.

737

738 Metagenomic library preparation and analysis

- 739 Samples were processed at University of Minnesota Genomics Center (UMGC) for library
- 740 preparation using the Nextera XT DNA Library Prep kit (Illumina), and metagenomic
- 741 sequencing on a NovaSeq (Illumina 2 x 150 bp reads). Resulting FASTQ files were processed
- 742 using quality filtering, adapter removal, human decontamination, and tandem repeat removal as
- described previously⁴⁰. Taxonomic classification and abundance estimation was performed using Kraken2 (v2.0.8-beta)⁴¹ and Bracken (v2.5)⁴². A custom Kraken2 database was used as described 743
- 744
- previously⁴⁰, with the addition of 165 novel skin genomes from Saheb Kashaf *et al.*⁶⁴. Reads 745
- 746 assigned as Homo sapiens or that were unclassified at the genus level were filtered out.
- 747 Decontam (v1.16.0) was then used to identify and remove contaminant reads using the
- 748 "prevalence" method, based on negative controls collected at time of swab collection and
- 749 processed with samples. See Supplemental Figure 2 for read counts at each step.
- 750

751 MTT assav

- 752 Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
- 753 bromide (MTT) colorimetric assay (Roche Diagnostics, Mannheim, Germany) per manufacturer
- 754 instructions. For the MTT assay, 10,000 neonatal human keratinocyte (HK; obtained from
- American Type Culture Collection (ATCC, Manassas, Virginia) cells were plated into a 96-well 755
- plate and cultured in a 5% CO₂ atmosphere at 37 °C. To determine the effect of the 756
- 757 Staphylococcus supernatants on HK cell viability, the cells were treated with HK media alone
- 758 (154 Human keratinocyte media (Thermo Fisher Scientific) supplemented with Human
- 759 Keratinocyte Growth Supplement and penicillin/streptomycin (Thermo Fischer Scientific)
- 760 additives) or HK media containing one of the Staphylococcus supernatants for 48 hours. The
- concentration of all supernatant treatments was standardized to $1*10^{6}$ CFU/mL. After the 761
- treatment period, HK were incubated in an MTT solution for 4 hours. A solubilization buffer was 762
- 763 then added to each well and the cells were incubated in a humidified atmosphere at 37°C
- 764 overnight. The absorbance was measured at 550 to 600 nm, with a reference wavelength of >650
- 765 nm, using a microplate reader (BioTek). The absorbance values were then used to determine cell
- 766 viability.
- 767
- 768
- 769

770 <u>SUPPLEMENTAL TABLE 1</u>

Table showing the medication usage and allergic co-morbidities of all subjects. AD = atopic

- dermatitis; FA = food allergy; F = female; M = male; N = no; Y = yes; * = irritant contact
- 773 dermatitis.
- 774
- 775

776 <u>SUPPLEMENTAL TABLE 2</u>

777	Table depicting the number of isolates of each species collected from each participant.
778	
779	
780	
781	
782	
783	
784	
785	
786	
787	
788	
789	
790	

791 <u>SUPPLEMENTAL FIGURE 1</u>

- 792 Diagram of the workflow.
- 793

794 SUPPLEMENTAL FIGURE 2

- 795 Count data at each filter step.
- 796

797 <u>SUPPLEMENTAL FIGURE 3</u>

- 798 Bar chart of the relative abundances of Eukaryotic (A) & Viral (B) species. Color and point
- shape correspond to AD status. *: p<0.05, **: p<0.01 <u>SUPPLEMENTAL FIGURE 4</u>
- 800 Bacterial Shannon Diversity Index broken out into evenness (A) & richness (B).

Figure 1









